Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...
The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback